CME 3 Session - EANM'16


Oncology/EORTC: Metabolic Response Assessment in Solid Tumors

Educational objectives:
  1. Learn about the methodological requirements for assessing response to treatment with PET and PET/CT
  2. Gain insight into the current clinical relevance of PET guided response assessment in breast and gynecological tumors, gastrointestinal tumors as well as bone and soft tissue sarcomas
  3. Understand what the challenges are of clinical adaptation of metabolic response assessment
  4. Learn on the perspectives of PET based response assessment in future clinical trials as well as in clinical routine


In times of increasing treatment options including targeted therapy and immunotherapy and only subgroups of patients benefiting from these toxic and expensive treatments there is an urgent need to identify patients responding or non-responding to treatment as early as possible after initiation of treatment. PET and PET/CT have been widely studied to metabolically assess response to therapy in numerous solid tumors but up to date still lack wide clinical adaption. Whereas in the US Medicare reimburses four PET scans in all solid tumors for subsequent treatment decision making it is much less accepted in Europe underlining the need to educate clinicians, imaging experts and governing bodies.

In this CME the presenters will address the methodological requirements to allow for metabolic response assessment, summarise the currently available clinical data for numerous solid tumors including breast and gynecological cancers, gastrointestinal tumors as well as bone and soft tissue sarcomas, discuss the challenges of metabolic response assessment and provide an outlook regarding future developments.

Key Words:

Response assessment, Treatment Monitoring, PET and PET/CT, standardisation

User action required
If you have the permission to view this publication, please log in.